Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KLN-1010 in Relapsed and Refractory Multiple Myeloma
NCT07075185Phase 1Recruiting
- Start
- Jul 2025
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of KLN-1010 in multiple myeloma (MM). Primary endpoint: Incidence and severity of treatment-emergent adverse events and dose-limiting toxicities at 15 years. Started Jul 2025; status: recruiting.
02
Drugs
KLN-1010
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07075185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07075185.